"By identifying and pursuing innovative products and technology, we intend to improve our cost structure, increase our market share, command better profit margins and reduce our operating risks," commented Mr. Zhang, the Company's Chief Financial Officer, "After we upgrade our existing facilities and complete the new glucose production complex in the first half of 2008, we will shift excess cornstarch to be utilized internally for pharmaceutical glucose production and other higher value-added products, which should further increase our profitability."
"We project that for the fiscal year ending June 30, 2008 we will achieve an after-tax net income of at least $9,000,000 or fully diluted earnings per share of at least $0.43," said Mr. Zhang.
A conference call will take place at 9:00 a.m. Eastern (U.S.) time on Friday, February 15, 2008. Anyone interested in participating should call 866- 800-8648 if calling from within the United States, or 617-614-2702 if calling internationally; the passcode is 835 628 35.
If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Friday, February 15 at 11:00 a.m. Eastern Time. To listen to the playback, please call 888-286-8010 if calling within the United States, or 617-801-6888 if calling internationally. Please use passcode 497 603 34 for the replay.
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary
Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese
operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a
leading manufacturer and supplier of glucose products, which include
pharmaceutical grade glucose use
|SOURCE Shengtai Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved